What Happened?
Shares of behavioral health company LifeStance Health (NASDAQ: LFST) jumped 11% in the afternoon session after the company reported mixed second-quarter 2025 results, delivering an earnings beat and a full-year profit forecast that topped Wall Street estimates. The mental healthcare provider's revenue for the quarter grew 10.6% year-over-year to $345.3 million, which was in line with analyst forecasts, driven by a 10.7% increase in sales volumes. On the bottom line, the company demonstrated improved profitability, posting a GAAP loss of $0.01 per share. This marked a significant improvement from the $0.06 per-share loss in the same period last year and beat consensus estimates for a $0.03 loss. Looking ahead, management provided a full-year Adjusted EBITDA forecast with a midpoint of $145 million, above analyst expectations. However, the company's revenue guidance for the next quarter came in below estimates, creating a mixed picture for investors.
Is now the time to buy LifeStance Health Group? Access our full analysis report here, it’s free.
What Is The Market Telling Us
LifeStance Health Group’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for LifeStance Health Group and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 21 days ago when the stock dropped 4% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities.
LifeStance Health Group is down 42.6% since the beginning of the year, and at $4.33 per share, it is trading 47% below its 52-week high of $8.17 from January 2025. Investors who bought $1,000 worth of LifeStance Health Group’s shares at the IPO in June 2021 would now be looking at an investment worth $197.77.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.
